Trexquant Investment LP purchased a new stake in Veracyte, Inc. (NASDAQ:VCYT – Get Rating) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 60,752 shares of the biotechnology company’s stock, valued at approximately $1,008,000. Trexquant Investment LP owned approximately 0.08% of Veracyte as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Pictet Asset Management SA grew its stake in Veracyte by 37.1% in the second quarter. Pictet Asset Management SA now owns 1,449,464 shares of the biotechnology company’s stock valued at $28,844,000 after purchasing an additional 392,169 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Veracyte during the 3rd quarter worth approximately $2,906,000. Fisher Asset Management LLC boosted its stake in shares of Veracyte by 17.8% during the 3rd quarter. Fisher Asset Management LLC now owns 1,737,508 shares of the biotechnology company’s stock worth $28,843,000 after acquiring an additional 262,223 shares during the period. ClariVest Asset Management LLC boosted its stake in shares of Veracyte by 56.8% during the 2nd quarter. ClariVest Asset Management LLC now owns 21,758 shares of the biotechnology company’s stock worth $433,000 after acquiring an additional 7,883 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Veracyte by 26.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 75,280 shares of the biotechnology company’s stock worth $1,498,000 after acquiring an additional 15,650 shares during the period.
Veracyte Price Performance
NASDAQ:VCYT opened at $22.68 on Tuesday. The stock has a 50 day simple moving average of $24.81 and a 200 day simple moving average of $23.01. Veracyte, Inc. has a 1-year low of $14.85 and a 1-year high of $32.40.
Insider Buying and Selling at Veracyte
In other Veracyte news, Director Bonnie H. Anderson sold 34,000 shares of Veracyte stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $26.35, for a total value of $895,900.00. Following the completion of the transaction, the director now directly owns 62,961 shares of the company’s stock, valued at approximately $1,659,022.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Veracyte news, Director Bonnie H. Anderson sold 34,000 shares of Veracyte stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $26.35, for a total value of $895,900.00. Following the completion of the transaction, the director now directly owns 62,961 shares of the company’s stock, valued at approximately $1,659,022.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bonnie H. Anderson sold 63,247 shares of Veracyte stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $25.13, for a total value of $1,589,397.11. Following the completion of the transaction, the director now directly owns 62,961 shares of the company’s stock, valued at $1,582,209.93. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Needham & Company LLC lifted their target price on Veracyte from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, February 23rd. Raymond James downgraded Veracyte from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 18th. Scotiabank started coverage on Veracyte in a report on Wednesday, January 4th. They set a “sector outperform” rating and a $33.00 price target for the company. Finally, StockNews.com raised Veracyte from a “sell” rating to a “hold” rating in a report on Tuesday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $30.20.
Veracyte Profile
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
Featured Articles
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Get Rating).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
